Arrowhead Pharmaceuticals (ARWR) – Research Analysts’ Weekly Ratings Changes

Arrowhead Pharmaceuticals (NASDAQ: ARWR) recently received a number of ratings updates from brokerages and research firms:

• 1/13/2026 – Arrowhead Pharmaceuticals had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $110.00 price target on the stock, up previously from $100.00.
• 1/7/2026 – Arrowhead Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $50.00 to $85.00. They now have a “neutral” rating on the stock.
• 1/7/2026 – Arrowhead Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $48.00 to $81.00. They now have an “equal weight” rating on the stock.
• 1/7/2026 – Arrowhead Pharmaceuticals had its price target raised by analysts at Chardan Capital from $60.00 to $80.00. They now have a “buy” rating on the stock.
• 12/17/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Piper Sandler from $70.00 to $100.00. They now have an “overweight” rating on the stock.
• 12/11/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $52.00 to $80.00. They now have an “outperform” rating on the stock.
• 12/9/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $62.00 to $81.00. They now have a “buy” rating on the stock.
• 12/2/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at HC Wainwright from $80.00 to $85.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Bank of America Corporation from $42.00 to $62.00. They now have a “buy” rating on the stock.
• 12/1/2025 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
• 11/26/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $45.00 to $48.00. They now have an “equal weight” rating on the stock.
• 11/20/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at The Goldman Sachs Group, Inc. from $27.00 to $48.00. They now have a “neutral” rating on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Royal Bank Of Canada from $45.00 to $52.00. They now have an “outperform” rating on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $60.00 price target on the stock.
• 11/19/2025 – Arrowhead Pharmaceuticals had its price target raised by analysts at Piper Sandler from $45.00 to $70.00. They now have an “overweight” rating on the stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, COO Patrick O’brien sold 49,493 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $3,123,503.23. Following the sale, the chief operating officer owned 474,908 shares in the company, valued at approximately $29,971,443.88. This trade represents a 9.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider James C. Hamilton sold 40,164 shares of the stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total value of $2,534,750.04. Following the transaction, the insider directly owned 171,958 shares in the company, valued at $10,852,269.38. The trade was a 18.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 510,836 shares of company stock valued at $33,603,060 over the last ninety days. Company insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.